Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is the most common and aggressive type of pancreatic cancer. The five-year survival rate of PDAC is very low (less than 8%), which is associated with the late diagnosis, high metastatic potential, and resistance to therapeutic agents. The identification of bet...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsieh, Yao-Yu, Liu, Tsang-Pai, Chou, Chia-Jung, Chen, Hsin-Yi, Lee, Kuen-Haur, Yang, Pei-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827004/
https://www.ncbi.nlm.nih.gov/pubmed/31569425
http://dx.doi.org/10.3390/genes10100766

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827004/
https://www.ncbi.nlm.nih.gov/pubmed/31569425
http://dx.doi.org/10.3390/genes10100766

Ejemplares similares